{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:31:45Z","timestamp":1788175905348,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This study aimed to evaluate the diagnostic roles of various immunohistochemical (IHC) markers in urothelial carcinoma in situ (uCIS) through a meta-analysis and review of diagnostic test accuracy. Materials and Methods: The IHC markers CK20, CD44, AMACR, and p53 were evaluated in the present study. We analyzed the expression rates of the IHC markers and compared their diagnostic accuracies. Results: The estimated expression rates were 0.803 (95% confidence interval [CI]: 0.726\u20130.862), 0.142 (95% CI: 0.033\u20130.449), 0.824 (95% CI: 0.720\u20130.895), and 0.600 (95% CI: 0.510\u20130.683) for CK20, CD44, AMACR, and p53, respectively. In the comparison between uCIS and reactive\/normal urothelium, the expression of CK20, AMACR, and p53 in uCIS was significantly higher than in reactive\/normal urothelium. CD44 showed significantly lower expression in uCIS than in the reactive\/normal urothelium. Among the markers, AMACR had the highest sensitivity, specificity, and diagnostic odds ratio. The AUC on SROC was the highest for CK20. Conclusions: In conclusion, IHC markers, such as CK20, CD44, AMACR, and p53, can be useful in differentiating uCIS from reactive\/normal urothelium.<\/jats:p>","DOI":"10.3390\/medicina59091609","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:14:14Z","timestamp":1693995254000},"page":"1609","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ"],"prefix":"10.3390","volume":"59","author":[{"given":"Daeseon","family":"Yoo","sequence":"first","affiliation":[{"name":"Department of Urology, Daejeon Eulji University Hospital, Eulji University School of Medicine, Daejeon 35233, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyueng-Whan","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Pathology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu-si 11759, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-8088","authenticated-orcid":false,"given":"Jung-Soo","family":"Pyo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu-si 11759, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-6385","authenticated-orcid":false,"given":"Nae Yu","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu-si 11759, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U","article-title":"Survival of patients with carcinoma in situ of the urinary bladder","volume":"85","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and a-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: Report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","article-title":"Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia","volume":"16","author":"Castillo","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","article-title":"Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: An analysis of cytokeratin 20, p53, and CD44 antigens","volume":"25","author":"McKenney","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00129039-200212000-00007","article-title":"p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder","volume":"10","author":"Sun","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13000-019-0871-8","article-title":"Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?","volume":"14","author":"Alston","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","article-title":"CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia","volume":"142","author":"Shah","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_11","first-page":"400","article-title":"Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67","volume":"30","author":"Asgari","year":"2016","journal-title":"Med. J. Islam. Repub. Iran"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: A switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.1991","article-title":"Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma","volume":"209","author":"Dhawan","year":"2006","journal-title":"J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/PAI.0b013e3182351ed3","article-title":"Utility of cytokeratin 5\/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia","volume":"20","author":"Edgecombe","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00428-021-03054-0","article-title":"Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: Implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer","volume":"479","author":"Garczyk","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5507\/bp.2020.017","article-title":"Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions","volume":"165","author":"Hacek","year":"2021","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0090-4295(96)00624-3","article-title":"Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Gu\u00e9rin treatment","volume":"49","author":"Ick","year":"1997","journal-title":"Urology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anndiagpath.2013.10.006","article-title":"The role of immunohistochemistry in the diagnosis of flat urothelial lesions: A study using CK20, CK5\/6, P53, Cd138, and Her2\/Neu","volume":"18","author":"Jung","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1827.2005.01821.x","article-title":"Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia","volume":"55","author":"Kunju","year":"2005","journal-title":"Pathol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAI.0000000000000872","article-title":"Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.humpath.2010.12.024","article-title":"Flat urothelial carcinoma in situ of the bladder with glandular differentiation","volume":"42","author":"Jimenez","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13000-020-00984-2","article-title":"CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia","volume":"15","author":"Neal","year":"2020","journal-title":"Diagn. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.humpath.2020.02.008","article-title":"Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap","volume":"98","author":"Nguyen","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.humpath.2012.08.011","article-title":"Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: A study of 45 cases","volume":"44","author":"Oliva","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00005392-199707000-00072","article-title":"Strong correlation of basement membrane degradation with p53 inactivation and\/or MDM2 overexpression in superficial urothelial carcinomas","volume":"158","author":"Ozdemir","year":"1997","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/PAS.0000000000001318","article-title":"Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases","volume":"43","author":"Sangoi","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1440-1827.2011.02694.x","article-title":"Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder","volume":"61","author":"Sato","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00184241","article-title":"P53 accumulation in precursor lesions and early stages of bladder cancer","volume":"12","author":"Grimm","year":"1994","journal-title":"World J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/01.ju.0000043638.89552.ed","article-title":"Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder","volume":"169","author":"Shariat","year":"2003","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3892\/mco.2021.2469","article-title":"Overexpression of the PPAR-\u03b3 protein in primary Ta\/T1 non-muscle-invasive urothelial carcinoma","volume":"16","author":"Tanaka","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zamora, J., Abraira, V., Muriel, A., Khan, K., and Coomarasamy, A. (2006). Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med. Res. Methodol., 6.","DOI":"10.1186\/1471-2288-6-31"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/sim.4780121403","article-title":"Combining independent studies of a diagnostic test into a summary ROC curve: Data-analytic approaches and some additional considerations","volume":"12","author":"Moses","year":"1993","journal-title":"Stat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bju.15746","article-title":"Ureteroscopy and tailored treatment of upper tract urothelial cancer: Recent advances and unmet needs","volume":"130","author":"Loizzo","year":"2022","journal-title":"BJU Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00345-023-04344-9","article-title":"Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome","volume":"41","author":"Cerrato","year":"2023","journal-title":"World J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.acuro.2022.02.004","article-title":"A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as im-munohistochemical markers in bladder carcinoma in situ","volume":"46","author":"Straccia","year":"2022","journal-title":"Actas Urol. Esp."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Aveta, A., Cilio, S., Contieri, R., Spena, G., Napolitano, L., Manfredi, C., Franco, A., Crocerossa, F., Cerrato, C., and Ferro, M. (2023). Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1974.v1"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1609\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:46:06Z","timestamp":1760129166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["medicina59091609"],"URL":"https:\/\/doi.org\/10.3390\/medicina59091609","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}